454 related articles for article (PubMed ID: 34738855)
41. PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy.
Le Gouill-Jaijarat C; Péréon Y; Leroy M; Lépine O; Loloum A; Peluchon C; Volteau C; Martineau AS; Korner S; Perrault C; Benmaziane A; Girot P; Petorin C; Perret C; Ligeza-Poisson C; Mayeur D; Flet L; Chiffoleau A; Poinas A; Bennouna J
Trials; 2023 Jan; 24(1):50. PubMed ID: 36670495
[TBL] [Abstract][Full Text] [Related]
42. Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale.
Kaiser K; Lyleroehr M; Shaunfield S; Lacson L; Corona M; Kircher S; Nittve M; Cella D
World J Gastrointest Oncol; 2020 Feb; 12(2):205-218. PubMed ID: 32104551
[TBL] [Abstract][Full Text] [Related]
43. Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2).
Motoo Y; Tomita Y; Fujita H
Int J Clin Oncol; 2020 Jun; 25(6):1123-1129. PubMed ID: 32232692
[TBL] [Abstract][Full Text] [Related]
44. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
Nepal MR; Taheri H; Li Y; Talebi Z; Uddin ME; Jin Y; DiGiacomo DF; Gibson AA; Lustberg MB; Hu S; Sparreboom A
Cancer Res Commun; 2022 Nov; 2(11):1334-1343. PubMed ID: 36506732
[TBL] [Abstract][Full Text] [Related]
45. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
46. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.
Cho K; Saikawa H; Hashimoto T; Katagiri H; Owada Y; Yakuwa K; Fujimura I; Utsumi Y; Akiyama M; Nagashima H; Takahashi F; Maemondo M
Ann Palliat Med; 2023 Nov; 12(6):1136-1145. PubMed ID: 37731302
[TBL] [Abstract][Full Text] [Related]
47. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
[TBL] [Abstract][Full Text] [Related]
48. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
Anastasio MK; Unnithan S; Scott A; Hayes T; Shah S; Moss HA; Erkanli A; Havrilesky LJ
Obstet Gynecol; 2023 Dec; 142(6):1459-1467. PubMed ID: 37883997
[TBL] [Abstract][Full Text] [Related]
49. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
50. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
[TBL] [Abstract][Full Text] [Related]
51. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.
Hsieh YL; Chou LW; Hong SF; Chang FC; Tseng SW; Huang CC; Yang CH; Yang CC; Chiu WF
Acupunct Med; 2016 Oct; 34(5):398-405. PubMed ID: 27613370
[TBL] [Abstract][Full Text] [Related]
52. Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial.
Trinh T; Park SB; Murray J; Pickering H; Lin CS; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV
Support Care Cancer; 2021 Feb; 29(2):1103-1110. PubMed ID: 32607598
[TBL] [Abstract][Full Text] [Related]
53. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
[TBL] [Abstract][Full Text] [Related]
54. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy.
Beijers AJM; Bonhof CS; Mols F; Ophorst J; de Vos-Geelen J; Jacobs EMG; van de Poll-Franse LV; Vreugdenhil G
Ann Oncol; 2020 Jan; 31(1):131-136. PubMed ID: 31912787
[TBL] [Abstract][Full Text] [Related]
55. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
Stefansson M; Nygren P
Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
[TBL] [Abstract][Full Text] [Related]
57. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
[TBL] [Abstract][Full Text] [Related]
58. A randomized, double-blind, placebo-controlled phase III trial of duloxetine in Japanese fibromyalgia patients.
Murakami M; Osada K; Mizuno H; Ochiai T; Alev L; Nishioka K
Arthritis Res Ther; 2015 Aug; 17(1):224. PubMed ID: 26296539
[TBL] [Abstract][Full Text] [Related]
59. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).
Joy L; Jolien R; Marithé C; Stijn E; Laura S; Hilde L; Sandra B; Wendy N; Ruth H; Liesbeth R; Sylvana S; Sylvia H; Jeroen M
Support Care Cancer; 2022 Jun; 30(6):5509-5517. PubMed ID: 35312857
[TBL] [Abstract][Full Text] [Related]
60. Prevention and treatment of chemotherapy-induced peripheral neuropathy.
Piccolo J; Kolesar JM
Am J Health Syst Pharm; 2014 Jan; 71(1):19-25. PubMed ID: 24352178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
